April 27, 2015
Sumitomo Dainippon Pharma said on April 24 that its atypical antipsychotic lurasidone (overseas brand name: Latuda) demonstrated no statistically significant improvement versus placebo in a key Asian PIII clinical study. “We think it will be difficult to file a new...read more